UniProt Q9BYP7 · PDB · AlphaFold · Substrate: MBP · Clone: Catalytic (1-434)
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Vemurafenib | 88.5% | 11.5% | 96.49 | 0.598 |
| 2 | Pacritinib | 56.0% | 44.0% | 88.64 | 0.452 |
| 3 | Neratinib | 46.0% | 54.0% | 93.18 | 0.597 |
| 4 | Dasatinib | 29.3% | 70.7% | 87.97 | 0.699 |
| 5 | Bosutinib | 23.1% | 76.9% | 87.22 | 0.555 |
| 6 | Tivozanib | 21.4% | 78.6% | 92.42 | 0.673 |
| 7 | Inavolisib | 20.9% | 79.1% | 100.00 | 0.679 |
| 8 | Fedratinib | 17.6% | 82.4% | 96.21 | 0.576 |
| 9 | Tucatinib | 17.2% | 82.8% | 99.75 | 0.652 |
| 10 | Leniolisib | 17.0% | 83.0% | 100.00 | 0.604 |
| 11 | Abrocitinib | 16.7% | 83.3% | 99.50 | 0.581 |
| 12 | Pexidartinib | 15.4% | 84.6% | 99.49 | 0.631 |
| 13 | Asciminib | 14.9% | 85.1% | 100.00 | 0.602 |
| 14 | Mitapivat | 14.9% | 85.1% | 100.00 | 0.625 |
| 15 | Alpelisib | 14.3% | 85.7% | 97.22 | 0.720 |
| 16 | Repotrectinib | 13.1% | 86.9% | 84.21 | 0.608 |
| 17 | Regorafenib | 12.7% | 87.3% | 95.99 | 0.719 |
| 18 | Avapritinib | 12.1% | 87.9% | 97.73 | 0.644 |
| 19 | Entrectinib | 12.0% | 88.0% | 93.69 | 0.671 |
| 20 | Futibatinib | 11.7% | 88.3% | 98.48 | 0.718 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.41
- Epithelial log2(TPM+1): 0.37
- Fold change: 0.04
- Status: No significant change
Selectivity landscape vs inhibition on WNK3
Each point is one of the 92 approved drugs; color = inhibition % on WNK3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…